DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided business updates and reported financial results for the second quarter
DUBLIN, June 24, 2021 /PRNewswire/ -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the pricing of its initial public offering in the United States of 10,000,000 ordinary shares at an
DUBLIN, April 12, 2021 /PRNewswire/ -- GH Research Ireland Ltd ("GH Research", "the Company" or "We") today announced the closing of a $125 million Series B financing co-led by RA Capital and RTW Investments, LP, U.S.-based biopharmaceutical investment firms, alongside existing investor BVF